^

Opinion

Medication combo trumps rosuvastatin in cutting LDL

YOUR DOSE OF MEDICINE - Charles C. Chante MD -

A combination of ezetimibe and simvastatin provides additional lipid-modifying benefits compared with rosuvastatin monotherapy among patients with type 2 diabetes or with metabolic syndrome without diabetes. Overall, ezetimibe/simvastatin, a single-tablet, dual-cholesterol inhibitor, offers an effective and well-tolerated lipid-modifying option for the treatment of hypercholesterolemia in patients with type 2 diabetes, and metabolic syndrome. In a post-hoc analysis of data from a multicenter, double-blind, randomized, six-week study, 375 patients with type 2 diabetes, 840 with metabolic syndrome but without diabetes, 1,722 with neither condition, and 22 who could not be placed in a category because of missing data were randomized to one of six treatment groups: ezetimibe/simvastatin (E/S) in doses of 10 mg/80 mg; or rosuvastatin ® in doses of 10, 20, or 40 mg. All had hypercholesterolemia, defined as an LDL-cholesterol level of 145-249 mg/DI (3.7-6.4)  with triglycerides at or below 350 mg/dL (4 mmol/L).

Among the whole cohort of 2,959 patients, significant reductions in LDL cholesterol from baseline were seen among the E/S group at the usual starting, next highest, and maximum dosing levels. Across all doses, the difference in LDL-cholesterol reduction between E/S and R was significant for the whole cohort (55.8% vs. 51.6%). Consistent with that, LDL-cholesterol lowering was also greater with E/S in the type 2 diabetes patients (58.5% vs. 54.2%).

Overall, 95.3% of the E/S group, compared with 92.1% of the R group, attained the recommended LDL-cholesterol goals of less than 100 mg/dL (2.6 mmol/L) for the diabetics, 130 mg/Dl (3.4 mmol/L) for the nondiabetics with metabolic syndrome, or 160 mg/Dl(4.1 mmol/L) for the group with neither. A total of 88.2% of the E/S patients versus 81.9% of the R patients achieved an LDL-cholesterol level of less than 100 mg/dL (2.6 mmol/L) whereas 45.3% vs. 29.5% reached an LDL cholesterol level of less than 70 mg/dL (1.8mmol/L).

All of these differences were significant. Reductions in total cholesterol, non-HDL cholesterol, apolipo-protein B, and triglycerides were also significantly greater with E/S; there were no significant differences between the two treatments in HDL cholesterol, or high-sensitivity C-reactive protein.

Both drugs showed similar rates of adverse events (8.1% E/S vs. 7.4%R) and discontinuations because of adverse events (2.2% for both drugs). Proteinuria was higher at baseline in the R group and among those with diabetes.

CHOLESTEROL

DIABETES

GROUP

LDL

MMOL

PATIENTS

S AND R

  • Latest
  • Trending
Latest
Latest
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with